MarketPeel
Insider Trading Intelligence
SL

Seth Lederman

TNXP
CHIEF EXECUTIVE OFFICER · TONIX PHARMACEUTICALS HOLDING CORP. · CIK 0001563420
FILING MIX · LIFETIME89%/11%
BUYS
24
SELLS
3
TOTAL VALUE
$598.1K
COMPANIES
1
ACTIVE SINCE
Feb 2020
HOLDINGS NOW
9,005
AVG SELL PX
$2.87
TRADE KIND
SHOWING 27 / 27
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
9 backtested trades · 8 horizons · 7 pendingHow are these numbers computed? →
Forward-return performance of every backtestable P/S trade by Seth Lederman, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d9+44.44%-0.21%+0.36%-0.57%-3.13%
14d9+22.22%+7.38%+1.63%+5.75%-8.87%
30d9+33.33%-1.19%+3.76%-4.95%-11.78%
60d9+33.33%-0.99%+4.33%-4.11%-18.15%
90d9+22.22%-1.59%+5.33%-6.93%-39.07%
180d9(2 pending)+28.57%-27.36%+7.42%-34.78%-65.23%
1y9(2 pending)+0.00%-68.86%+14.32%-83.18%-81.06%
2y9(3 pending)+0.00%-98.57%+18.24%-116.80%-110.92%
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
TNXP · 9,005 shares · as of Jun 9, 2026
01,250,0002,500,0003,750,0005,000,000202120222023202420252026SHARES HELD
Trading cadence · quarterly flow
BUY SELL
2020
2020
2020
2020
2021
2021
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
FLOW · 24 buys / 3 sellsCOVERAGE · 26 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
TNXP
TONIX PHARMACEUTICALS HOLDING CORP.
PURCHASE
Chief Executive Officer
5,000$11.79$59.0K9,005Jun 9, 2026Jun 9, 2026View →
TNXP
TONIX PHARMACEUTICALS HOLDING CORP.
PURCHASE
Chief Executive Officer
5,000$12.62$63.1K20,001Mar 31, 2026Apr 1, 2026View →
TNXP
TONIX PHARMACEUTICALS HOLDING CORP.
PURCHASE
Chief Executive Officer
15,000$14.89$223.3K15,001Mar 18, 2026Mar 18, 2026View →
TNXP
TONIX PHARMACEUTICALS HOLDING CORP.
PURCHASEGRANT
Stock grant
134,504134,504Feb 24, 2026Feb 26, 2026View →
TNXP
TONIX PHARMACEUTICALS HOLDING CORP.
PURCHASEGRANT
Stock grant
134,503134,503Feb 24, 2026Feb 26, 2026View →
TNXP
TONIX PHARMACEUTICALS HOLDING CORP.
PURCHASE
Chief Executive Officer
4,000$21.55$86.2K4,005May 15, 2025May 15, 2025View →
TNXP
TONIX PHARMACEUTICALS HOLDING CORP.
PURCHASEGRANT
Stock grant
123,958123,958Feb 25, 2025Feb 27, 2025View →
TNXP
TONIX PHARMACEUTICALS HOLDING CORP.
SALE
Chief Executive Officer
5.18$3.38$185Feb 5, 2025Feb 27, 2025View →
TNXP
TONIX PHARMACEUTICALS HOLDING CORP.
SALE
Chief Executive Officer
1$0.15$00Feb 5, 2025Feb 27, 2025View →
TNXP
TONIX PHARMACEUTICALS HOLDING CORP.
SALE
Chief Executive Officer
0.22$3.30$11Feb 5, 2025Feb 27, 2025View →
TNXP
TONIX PHARMACEUTICALS HOLDING CORP.
PURCHASEGRANT
Stock grant
1,309,9111,309,911Feb 27, 2024Mar 6, 2024View →
TNXP
TONIX PHARMACEUTICALS HOLDING CORP.
PURCHASEGRANT
Stock grant
235,320235,320Feb 27, 2024Mar 6, 2024View →
TNXP
TONIX PHARMACEUTICALS HOLDING CORP.
PURCHASEGRANT
Stock grant
1,903,6801,903,680Feb 27, 2024Mar 6, 2024View →
TNXP
TONIX PHARMACEUTICALS HOLDING CORP.
PURCHASEGRANT
Stock grant
235,320235,320Feb 27, 2024Feb 29, 2024View →
TNXP
TONIX PHARMACEUTICALS HOLDING CORP.
PURCHASEGRANT
Stock grant
1,903,6801,903,680Feb 27, 2024Feb 29, 2024View →
TNXP
TONIX PHARMACEUTICALS HOLDING CORP.
PURCHASEGRANT
Stock grant
1,309,9111,309,911Feb 27, 2024Feb 29, 2024View →
TNXP
TONIX PHARMACEUTICALS HOLDING CORP.
PURCHASEGRANT
Stock grant
700,000700,000Feb 23, 2023Feb 24, 2023View →
TNXP
TONIX PHARMACEUTICALS HOLDING CORP.
PURCHASE
Chief Executive Officer
20,000$1.71$34.2K24,235Jun 29, 2022Jul 1, 2022View →
TNXP
TONIX PHARMACEUTICALS HOLDING CORP.
PURCHASE
Chief Executive Officer
100,000$0.25$24.5K112,177Mar 25, 2022Mar 25, 2022View →
TNXP
TONIX PHARMACEUTICALS HOLDING CORP.
PURCHASEGRANT
Stock grant
5,000,0005,000,000Feb 15, 2022Feb 17, 2022View →
TNXP
TONIX PHARMACEUTICALS HOLDING CORP.
PURCHASE
Chief Executive Officer
12,000$0.61$7.3K12,177Sep 28, 2021Sep 28, 2021View →
TNXP
TONIX PHARMACEUTICALS HOLDING CORP.
PURCHASE
Chief Executive Officer
16,733$1.32$22.1K135,000Mar 24, 2021Mar 25, 2021View →
TNXP
TONIX PHARMACEUTICALS HOLDING CORP.
PURCHASEGRANT
Stock grant
3,000,0003,000,000Feb 23, 2021Feb 25, 2021View →
TNXP
TONIX PHARMACEUTICALS HOLDING CORP.
PURCHASE
Chief Executive Officer
35,000$0.68$23.8K118,267Dec 30, 2020Dec 30, 2020View →
TNXP
TONIX PHARMACEUTICALS HOLDING CORP.
PURCHASE
Chief Executive Officer
60,000$0.91$54.6K83,267Aug 13, 2020Aug 17, 2020View →
TNXP
TONIX PHARMACEUTICALS HOLDING CORP.
PURCHASEGRANT
Stock grant
2,000,0002,000,000May 4, 2020May 6, 2020View →
TNXP
TONIX PHARMACEUTICALS HOLDING CORP.
PURCHASEGRANT
Stock grant
120,000120,000Feb 25, 2020Feb 27, 2020View →
Other insiders · TNXP
Loading peer insiders…
About this filer
CIK 0001563420
ROLE
Chief Executive Officer
PRIMARY
TNXP
COMPANIES
1
ACTIVE SINCE
Feb 2020
MARKETPEEL · /INSIDER/0001563420DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback